Last updated: September 7, 2026
Evinacumab-dgnb, marketed as Evkeeza by Regeneron Pharmaceuticals, is a first-in-class monoclonal antibody for homozygous familial hypercholesterolemia, or HoFH. Its commercial profile combines a very small addressable population, high annual treatment cost, durable biologic exclusivity, and limited direct therapeutic competition. Regeneron reported Evkeeza net product sales of approximately $173 million in 2023, up from about $127 million in 2022 and $49 million in 2021.[1][2]
The product is commercially important as a rare-disease franchise, but its revenue ceiling is constrained by HoFH prevalence, diagnosis rates, payer controls, and the availability of other LDL-lowering therapies.
What is evinacumab-dgnb and how does it work?
Evinacumab-dgnb is a fully human monoclonal antibody that binds angiopoietin-like protein 3, or ANGPTL3. It reduces LDL cholesterol through an LDL receptor-independent mechanism, which is important in HoFH patients whose LDL receptor function is severely impaired.[3]
| Attribute |
Evinacumab-dgnb |
| Brand name |
Evkeeza |
| Developer and marketer |
Regeneron Pharmaceuticals |
| Target |
ANGPTL3 |
| Therapeutic class |
Monoclonal antibody |
| FDA indication |
Adjunct to other LDL-lowering treatments for patients aged 5 years and older with HoFH |
| FDA approval |
February 11, 2021 |
| Administration |
Intravenous infusion once every four weeks |
| Dose |
15 mg/kg |
| Biologic license application |
BLA 761181 |
| Exclusivity profile |
Biologic data exclusivity, orphan-drug exclusivity, patent protection |
The FDA approved Evkeeza based on reductions in LDL cholesterol in the ELIPSE HoFH trial. At week 24, the treatment difference versus placebo was approximately 47.1%.[3] The therapy is used with statins, ezetimibe, PCSK9 inhibitors, lomitapide, and other background treatments. Some patients also require LDL apheresis.
What is the commercial market for Evkeeza?
The addressable market is concentrated in HoFH, a rare inherited disorder characterized by extremely high LDL cholesterol and premature atherosclerotic cardiovascular disease.
Published prevalence estimates vary. HoFH is often estimated at roughly one patient per 300,000 to one million people, although genetic screening and improved diagnosis have increased identified cases.[4] The treated population is therefore small relative to conventional lipid-lowering markets.
Estimated market characteristics
| Market factor |
Commercial effect |
| Very low disease prevalence |
Limits total patient volume |
| Severe cardiovascular risk |
Supports treatment urgency |
| LDL receptor-independent mechanism |
Creates differentiation in genetically severe disease |
| Intravenous administration |
Increases site-of-care and infusion burden |
| High annual price |
Supports revenue per patient but increases payer scrutiny |
| Pediatric approval |
Expands lifetime treatment opportunity |
| Chronic treatment |
Creates recurring revenue |
| Combination use |
Positions Evkeeza as an add-on rather than a replacement therapy |
The U.S. wholesale acquisition cost has been reported at approximately $450,000 per patient annually, although actual net pricing depends on discounts, payer arrangements, patient assistance, and treatment weight.[5] At that price, a few hundred treated patients can generate meaningful revenue. The product still requires broad identification of undiagnosed HoFH patients to reach its commercial potential.
What has been Evkeeza’s financial trajectory?
Regeneron’s reported net product sales show rapid growth after launch, followed by the expected pattern of expansion from a small base.
| Fiscal year |
Evkeeza net product sales |
Approximate year-over-year change |
| 2021 |
$49 million |
Launch year |
| 2022 |
$127 million |
159% |
| 2023 |
$173 million |
36% |
Sources: Regeneron annual reports and Form 10-K filings.[1][2]
The trajectory indicates successful market uptake, but not a mass-market product profile. The principal growth drivers have been:
- Increased diagnosis of HoFH.
- Greater physician familiarity with ANGPTL3 inhibition.
- Expanded use in patients inadequately controlled on existing therapy.
- Pediatric availability following the FDA’s expansion of the indication to patients aged five years and older.[6]
- International commercialization and reimbursement expansion.
Growth is likely to moderate as the readily identifiable treatment population becomes penetrated. Future revenue depends more on patient finding, global access, and treatment persistence than on broad prescriber adoption.
How does Evkeeza compare with competing HoFH therapies?
Evkeeza competes with established therapies that have different mechanisms, administration requirements, and safety profiles.
| Therapy |
Mechanism |
Administration |
Position in HoFH |
| Evkeeza |
ANGPTL3 inhibition |
IV every four weeks |
Add-on therapy with LDL receptor-independent activity |
| Lomitapide |
MTP inhibition |
Oral daily |
Potent LDL reduction; gastrointestinal and hepatic monitoring |
| Evolocumab |
PCSK9 inhibition |
Subcutaneous |
Less effective when LDL receptor function is severely impaired |
| Alirocumab |
PCSK9 inhibition |
Subcutaneous |
Similar LDL receptor dependence |
| Inclisiran |
PCSK9 siRNA |
Subcutaneous, less frequent dosing |
Emerging option; limited HoFH-specific experience |
| LDL apheresis |
Extracorporeal LDL removal |
Repeated procedural treatment |
Effective but burdensome and resource-intensive |
| Statins and ezetimibe |
HMG-CoA reductase and cholesterol absorption inhibition |
Oral |
Background treatment |
Evkeeza’s principal competitive advantage is its LDL receptor-independent activity. Its main disadvantages are intravenous delivery, infusion-center dependence, and the need for chronic combination treatment.
Lomitapide remains a direct commercial competitor in severe HoFH. Its oral administration is attractive, but hepatic monitoring, gastrointestinal tolerability, and dietary restrictions can limit use. PCSK9 inhibitors are less differentiated in receptor-defective disease but remain important because of their broad availability and lower logistical burden.
What patents protect evinacumab-dgnb?
Protection for Evkeeza is based on a combination of biologic exclusivity, antibody-related patent claims, manufacturing claims, formulation claims, and method-of-use claims.
Because Evkeeza is licensed under a biologics license application, it is not treated like a conventional small-molecule product with a standard Orange Book patent listing. Its principal FDA reference is the Purple Book, which identifies licensed biological products and biosimilar relationships.[7]
Core protection categories
| Protection category |
Relevance to Evkeeza |
| Antibody composition claims |
Cover antibodies binding ANGPTL3 or defined epitopes |
| Sequence claims |
Cover heavy-chain, light-chain, and complementary-determining-region sequences |
| Pharmaceutical composition claims |
Cover antibody formulations and excipient systems |
| Treatment claims |
Cover reducing LDL cholesterol or treating HoFH |
| Manufacturing claims |
Cover production, purification, and formulation processes |
| Regulatory exclusivity |
Delays biosimilar approval and commercial competition |
Regeneron’s broader ANGPTL3 patent portfolio was developed before approval and includes antibody and therapeutic-use inventions. Patent expiry dates vary by claim and jurisdiction. The effective exclusivity period will depend on which claims survive validity and infringement challenges, any patent-term adjustment or extension, and the date of any biosimilar approval.
The 12-year U.S. reference-product exclusivity period for a biologic approved on February 11, 2021 generally prevents FDA approval of a biosimilar referencing Evkeeza until February 2033, subject to statutory rules and regulatory developments.[8] Orphan-drug exclusivity is generally seven years from approval, placing the U.S. orphan period around February 2028.[9] Patent protection can extend beyond both periods.
When does Evkeeza lose exclusivity?
The main U.S. regulatory milestones are:
| Milestone |
Approximate date |
| FDA approval |
February 11, 2021 |
| Orphan-drug exclusivity expiry |
February 2028 |
| First potential biosimilar application approval window based on 12-year exclusivity |
February 2033 |
| Potential commercial biosimilar entry |
Dependent on patent resolution, litigation, settlements, and FDA approval |
| Patent expiry |
Claim-specific; some protection may extend beyond 2033 |
The first practical biosimilar entry date is unlikely to be determined solely by the 12-year biologic exclusivity period. A biosimilar sponsor must also address patent claims, regulatory interchangeability strategy, manufacturing comparability, and commercial economics.
What is the FDA and Orange Book status of Evkeeza?
Evkeeza is FDA-approved under BLA 761181. It is a biologic, not a traditional small-molecule drug approved under an NDA. As a result, the Orange Book is not the primary patent-reference database for this product.[3][7]
The relevant regulatory framework is the Public Health Service Act, including the abbreviated pathway for biosimilars. A biosimilar sponsor may submit an abbreviated biologics license application, or aBLA, showing biosimilarity to the reference product. Interchangeability is a separate regulatory designation and is not required for biosimilar approval.
No established U.S. generic pathway applies to evinacumab-dgnb. Any competitive follow-on product would be a biosimilar, not an ANDA-approved generic.
Are there Paragraph IV challenges or patent lawsuits against Evkeeza?
Paragraph IV litigation is associated with Hatch-Waxman small-molecule products and Orange Book patents. It is not the standard litigation mechanism for Evkeeza because the product is a biologic approved under a BLA.
Biosimilar disputes would instead arise under the Biologics Price Competition and Innovation Act, including the statutory patent-exchange process often called the "patent dance." Potential disputes could involve:
- Antibody sequence and epitope claims.
- ANGPTL3-binding claims.
- Formulation and stability claims.
- Manufacturing and purification claims.
- Treatment methods for HoFH.
- Patent-term adjustment and patent-term extension calculations.
No major public U.S. biosimilar litigation or settlement involving evinacumab-dgnb was established in the public record through June 2024. The absence of litigation at that point reflected the product’s relatively early commercial age and the limited near-term biosimilar incentive.
How strong is the Evkeeza patent estate?
The estate is commercially meaningful but not invulnerable.
Strengths
- First-mover position for an ANGPTL3 antibody in HoFH.
- Biologic reference-product exclusivity through approximately 2033.
- Orphan exclusivity through approximately 2028.
- Multiple possible claim types beyond a single composition patent.
- Complex biologic manufacturing process.
- Limited patient population reduces the immediate incentive for biosimilar developers.
Weaknesses
- The target and therapeutic concept are publicly established.
- Follow-on antibodies could challenge narrow sequence or epitope claims.
- Method-of-use claims may be narrower than composition claims.
- The commercial market may not support multiple expensive biosimilars.
- Manufacturing complexity does not eliminate the possibility of biosimilar competition.
The strongest protection is likely to come from valid composition and sequence claims combined with regulatory exclusivity. Formulation and treatment-method patents can extend litigation leverage but may be more vulnerable to design-around strategies.
What licensing deals affect evinacumab-dgnb?
Regeneron originally collaborated with Ultragenyx Pharmaceutical on the development and commercialization of evinacumab. Regeneron later obtained global rights to the program from Ultragenyx in 2020 before the FDA approval.[10]
The transaction consolidated global control of development, regulatory strategy, manufacturing, and commercialization with Regeneron. It also removed the need to divide economics across two commercial organizations, although the precise financial terms and continuing obligations are subject to the transaction agreements and company disclosures.
What generic or biosimilar entry risks exist?
The most credible U.S. entry scenario is a biosimilar launch after the early 2030s, assuming a sponsor completes development and resolves patent barriers.
| Entry scenario |
Timing |
Probability assessment |
| No near-term U.S. biosimilar |
Before 2030 |
High |
| Patent challenge during the early 2030s |
Around or before 2033 |
Plausible |
| First U.S. biosimilar approval |
After reference-product exclusivity |
Plausible |
| Immediate multi-sponsor erosion |
After first approval |
Low to moderate |
| Price erosion comparable to small molecules |
Long term |
Unlikely |
| Gradual payer-driven discounting |
After biosimilar entry |
Likely |
The small HoFH population limits the number of commercially viable entrants. At the same time, high annual treatment costs create a large gross-price spread that could support biosimilar development if diagnosis expands.
What is the revenue exposure for Regeneron?
Evkeeza is unlikely to approach the revenue scale of Regeneron’s largest products, including Eylea and Dupixent-related economics. Its value is concentrated in rare-disease pricing, strategic control of the ANGPTL3 platform, and recurring treatment of a high-risk population.
The principal revenue risks are:
- Slower diagnosis of HoFH.
- Reimbursement delays.
- Patient switching to lomitapide or apheresis.
- Infusion-center capacity constraints.
- Restrictive prior authorization.
- Limited penetration outside major specialty centers.
- Long-term biosimilar competition.
- Better tolerated oral or subcutaneous therapies.
The principal upside drivers are:
- Expanded genetic testing.
- Earlier pediatric treatment.
- Broader international reimbursement.
- Improved cardiovascular-risk recognition.
- Use in patients unable to tolerate lomitapide.
- Additional ANGPTL3 indications, if successfully developed.
Key Takeaways
- Evkeeza is the first approved ANGPTL3 inhibitor and is differentiated by LDL receptor-independent activity.
- Regeneron reported approximately $173 million in 2023 net product sales, compared with $127 million in 2022.
- The commercial market is small but supports high revenue per patient.
- U.S. biologic exclusivity generally extends through February 2033, while orphan exclusivity runs approximately through February 2028.
- Evkeeza is a BLA product and does not follow the conventional Orange Book and Paragraph IV framework.
- Biosimilar risk is limited before the early 2030s but could become material after regulatory exclusivity expires.
- The largest commercial constraints are HoFH diagnosis, infusion delivery, payer controls, and competition from lomitapide and LDL apheresis.
- Regeneron’s acquisition of global rights from Ultragenyx consolidated the product’s commercial economics.
FAQs About Evinacumab-Dgnb
Is Evkeeza a statin or PCSK9 inhibitor?
No. Evkeeza is a monoclonal antibody against ANGPTL3. Its LDL-lowering effect is substantially independent of LDL receptor activity.
Can evinacumab-dgnb be used in heterozygous familial hypercholesterolemia?
The FDA-approved indication is HoFH. Use in heterozygous familial hypercholesterolemia would depend on clinical evidence, regulatory labeling, and payer coverage.
Is Evkeeza administered at home?
Evkeeza is administered by intravenous infusion by a qualified health-care professional. It is generally delivered in an infusion setting rather than by self-injection at home.
Will the first Evkeeza biosimilar automatically be interchangeable?
No. Biosimilar approval and interchangeability are separate FDA determinations. A biosimilar can be approved without receiving an interchangeable designation.
Does Evkeeza have orphan-drug pricing protection after 2028?
Orphan-drug exclusivity does not prevent all competition after its expiration. Patent protection, biologic reference-product exclusivity, regulatory requirements, and payer contracting can continue to affect competitive entry and pricing.
References
- Regeneron Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023.
- Regeneron Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022.
- U.S. Food and Drug Administration. (2021). Evkeeza prescribing information.
- Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., Tybjærg-Hansen, A., Watts, G. F., & European Atherosclerosis Society Consensus Panel. (2014). Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. European Heart Journal, 35(32), 2146-2157.
- Regeneron Pharmaceuticals, Inc. (2024). Evkeeza product and access information.
- U.S. Food and Drug Administration. (2023). FDA expands approval of Evkeeza for pediatric patients with homozygous familial hypercholesterolemia.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262(k).
- Orphan Drug Act, 21 U.S.C. § 360cc.
- Ultragenyx Pharmaceutical Inc. (2020). Corporate and regulatory disclosures concerning the transfer of global evinacumab rights to Regeneron Pharmaceuticals.
